{"id":1079,"date":"2026-02-11T18:06:16","date_gmt":"2026-02-11T18:06:16","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/1079\/"},"modified":"2026-02-11T18:06:16","modified_gmt":"2026-02-11T18:06:16","slug":"roches-genentech-more-than-doubles-north-carolina-facility-investment-to-2b-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/1079\/","title":{"rendered":"Roche\u2019s Genentech more than doubles North Carolina facility investment to $2B"},"content":{"rendered":"\n

This story was originally published on Manufacturing Dive<\/a>. To receive daily news and insights, subscribe to our free daily Manufacturing Dive newsletter<\/a>. <\/p>\n

Genentech, a subsidiary of Roche Group, will more than double<\/a> its initial investment in an upcoming Holly Springs, North Carolina, biomanufacturing facility to $2 billion, the San Francisco-based company said Tuesday.<\/p>\n

The additional capital will allow the company to increase production volume and scale capacity within the facility, as well as create a total of 500 local manufacturing jobs, according to a news release. The plant is set to be operational by 2029.<\/p>\n

Genentech initially pledged $700 million<\/a> last year to build the Holly Springs factory, its first on the East Coast. The location is designed to produce weight-loss treatments and other metabolic medicines. Construction on the project began in August.<\/p>\n

The expansion is part of a broader $50 billion commitment<\/a> from Genentech and Roche to improve their U.S. operational footprint. Pharmaceutical giants such as Lilly<\/a> and Johnson & Johnson<\/a> have made similar pledges over the next five years in response to shifting customer demand as the Trump administration\u2019s tariffs disrupt supply chains, markets and production.<\/p>\n

\u201cThis additional investment will create more high-quality jobs, strengthen local partnerships, and ensure a resilient supply of medicines for years to come, allowing us to bring life-changing medicines to patients faster and more reliably,\u201d Genentech CEO Ashley Magargee said in a statement.<\/p>\n

The company said it increased its investment due, in part, to the skilled local workforce and strong academic institutions in the Raleigh-Durham area. Holly Springs has rapidly emerged as a national biopharmaceutical hub, attracting investments from Fujifilm Diosynth Biotechnologies<\/a> and Amgen<\/a> in recent years. Genentech\u2019s 700,000-square-foot project will be outfitted with advanced biomanufacturing, automation and digital tools to boost efficiency and sustainability, the company said.<\/p>\n

Genentech received a $13.1 million state incentive package for the project, including a job creation grant worth $9.8 million, according to the North Carolina Department of Commerce<\/a>. The average salary of the new positions will be about $120,000.<\/p>\n

Currently, Roche and Genentech have 13 manufacturing and 15 research and development facilities across the nation, supporting 25,000 employees, according to a news release. As part of their broader U.S. investment plans, they are expanding and upgrading facilities in Kentucky, Indiana, New Jersey, Oregon and California.<\/p>\n","protected":false},"excerpt":{"rendered":"This story was originally published on Manufacturing Dive. To receive daily news and insights, subscribe to our free…\n","protected":false},"author":2,"featured_media":1080,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[1363,1360,1361,250,118,1362,134,1359],"class_list":{"0":"post-1079","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-biomanufacturing","9":"tag-genentech","10":"tag-holly-springs","11":"tag-investment","12":"tag-north-carolina","13":"tag-production-volume","14":"tag-roche","15":"tag-roche-group"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/1079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=1079"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/1079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/1080"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=1079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=1079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=1079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}